Bharat Biotech’s Covaxin now in Phase III trials

Our Bureau Hyderabad | Updated on November 16, 2020

Single dose nasal vaccine may be ready by next year, Says Krishna Ella

Covid-19 vaccine, Covaxin, is now undergoing phase-III trials, according to , Krishna Ella, Chairman and Managing Director, Bharat Biotech.

“As we speak today, Covaxin has entered Phase-III trials,” Krishna Ella, said while speaking at the Deccan Dialogue of Indian School of Business (ISB) on Monday.

Also read: Bharat Biotech to launch Covaxin in Q2 2021

Referring to the task of providing access to 1.3 billion people of the country, he said a two-dose vaccine require 2.6 million doses with logistics support adding that it was a ‘worrying’ factor. Bharat Biotech had also geared up for production, Ella said.

Nasal Vaccine

“We are also working on a single dose nasal drop vaccine may be ready by next year,” he said.

Also read: Bharat Biotech inks licensing deal with Washington University School of Medicine for Covid-19 intranasal vaccine technology

The Hyderabad-based Bharat Biotech worked with the Indian Council of Medical Research to develop Covaxin.

Published on November 16, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor